Intravenous Gammaglobulin Treatment in HIV-1 Infection

Avi Deener; Ami Mehra; Larry Bernstein; Jenny Shliozberg; Arye Rubinstein

doi:10.1016/j.iac.2008.06.001

Intravenous Gammaglobulin Treatment in HIV-1 Infection

Avi Deener, Ami Mehra, Larry Bernstein, Jenny Shliozberg, Arye Rubinstein

Pediatrics

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

The two main indications for the use of intravenous gammaglobulin-antibody replacement therapy and immunomodulation-are pertinent only for a few scenarios in HIV-1 infection. The role of gammaglobulin in the treatment of HIV-1 infection has changed significantly with the introduction of highly active antiretroviral therapy. Antiretroviral drugs have not only controlled the progression of disease but also had far-reaching effects on HIV-1-induced immunologic aberrations. Complete or partial immunologic reconstitution and prevention of immunologic damage have been the hallmarks of success for highly active antiretroviral therapy. This article addresses the use of gammaglobulin before and after the era of effective antiretroviral therapies.

Original language	English (US)
Pages (from-to)	851-859
Number of pages	9
Journal	Immunology and Allergy Clinics of North America
Volume	28
Issue number	4
DOIs	https://doi.org/10.1016/j.iac.2008.06.001
State	Published - Nov 2008

Keywords

AIDS
B cells
HIV-1
Highly active antiretroviral therapy (HAART)
Immunodeficiency
Opportunistic infections
T cells
Thrombocytopenia

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.iac.2008.06.001

Cite this

@article{8db1ea2a0f094a178517efdace6f2ec9,

title = "Intravenous Gammaglobulin Treatment in HIV-1 Infection",

abstract = "The two main indications for the use of intravenous gammaglobulin-antibody replacement therapy and immunomodulation-are pertinent only for a few scenarios in HIV-1 infection. The role of gammaglobulin in the treatment of HIV-1 infection has changed significantly with the introduction of highly active antiretroviral therapy. Antiretroviral drugs have not only controlled the progression of disease but also had far-reaching effects on HIV-1-induced immunologic aberrations. Complete or partial immunologic reconstitution and prevention of immunologic damage have been the hallmarks of success for highly active antiretroviral therapy. This article addresses the use of gammaglobulin before and after the era of effective antiretroviral therapies.",

keywords = "AIDS, B cells, HIV-1, Highly active antiretroviral therapy (HAART), Immunodeficiency, Opportunistic infections, T cells, Thrombocytopenia",

author = "Avi Deener and Ami Mehra and Larry Bernstein and Jenny Shliozberg and Arye Rubinstein",

year = "2008",

month = nov,

doi = "10.1016/j.iac.2008.06.001",

language = "English (US)",

volume = "28",

pages = "851--859",

journal = "Immunology and Allergy Clinics of North America",

issn = "0889-8561",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Intravenous Gammaglobulin Treatment in HIV-1 Infection

AU - Deener, Avi

AU - Mehra, Ami

AU - Bernstein, Larry

AU - Shliozberg, Jenny

AU - Rubinstein, Arye

PY - 2008/11

Y1 - 2008/11

N2 - The two main indications for the use of intravenous gammaglobulin-antibody replacement therapy and immunomodulation-are pertinent only for a few scenarios in HIV-1 infection. The role of gammaglobulin in the treatment of HIV-1 infection has changed significantly with the introduction of highly active antiretroviral therapy. Antiretroviral drugs have not only controlled the progression of disease but also had far-reaching effects on HIV-1-induced immunologic aberrations. Complete or partial immunologic reconstitution and prevention of immunologic damage have been the hallmarks of success for highly active antiretroviral therapy. This article addresses the use of gammaglobulin before and after the era of effective antiretroviral therapies.

AB - The two main indications for the use of intravenous gammaglobulin-antibody replacement therapy and immunomodulation-are pertinent only for a few scenarios in HIV-1 infection. The role of gammaglobulin in the treatment of HIV-1 infection has changed significantly with the introduction of highly active antiretroviral therapy. Antiretroviral drugs have not only controlled the progression of disease but also had far-reaching effects on HIV-1-induced immunologic aberrations. Complete or partial immunologic reconstitution and prevention of immunologic damage have been the hallmarks of success for highly active antiretroviral therapy. This article addresses the use of gammaglobulin before and after the era of effective antiretroviral therapies.

KW - AIDS

KW - B cells

KW - HIV-1

KW - Highly active antiretroviral therapy (HAART)

KW - Immunodeficiency

KW - Opportunistic infections

KW - T cells

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=53649095064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53649095064&partnerID=8YFLogxK

U2 - 10.1016/j.iac.2008.06.001

DO - 10.1016/j.iac.2008.06.001

M3 - Review article

C2 - 18940578

AN - SCOPUS:53649095064

SN - 0889-8561

VL - 28

SP - 851

EP - 859

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

IS - 4

ER -

Intravenous Gammaglobulin Treatment in HIV-1 Infection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this